News stories about Aratana Therapeutics (NASDAQ:PETX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.4880856312586 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several analysts recently issued reports on the stock. BidaskClub raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 10th. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine upgraded shares of Aratana Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 2nd. CL King upgraded shares of Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Monday, March 12th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.68.
Aratana Therapeutics traded up $0.08, hitting $4.61, during trading hours on Friday, MarketBeat reports. 1,355,874 shares of the company traded hands, compared to its average volume of 438,081. The stock has a market cap of $231.41 million, a P/E ratio of -4.75 and a beta of 2.86. Aratana Therapeutics has a twelve month low of $3.67 and a twelve month high of $7.67. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.37 and a quick ratio of 2.82.
In other news, insider Peter Steven St sold 11,513 shares of the stock in a transaction on Monday, April 30th. The shares were sold at an average price of $5.00, for a total value of $57,565.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.30% of the stock is owned by corporate insiders.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.